Sign in
Active, not recruitingNo phase

Treat-to-target by Email During Urate-lowering Therapy in Gout

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
204 people, planned
Started
15 Dec 2021
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cleanweb electronic messaging ePro
  • Usual follow-up
Record updated
4 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adults aged over 18 years old
  • Gout confirmed by identification of urate crystals by joint fluid or tophus analysis or by ultrasound of the affected joint or
  • Gout according to Nijmegen criteria (presence of a score ≥ 8/13) depending on the following items:; Man (2 pts) Previous crisis (2 pts) Involvement of first metatarsophalangeal joint (MTP1) (2.5 pts) Maximum pain within 24 hours (0.5pt) Redness (1 pt) HTA or cardiovascular disease (1.5 pts) SUL > 360 μmol/l during the crisis (3.5 pts)
  • Patients without ULT or with an ineffective ULT defined by an SUL > 360 μmol/l in intercritical pahse
  • Patients who routinely use e-mail

Who cannot take part

  • Participating in another trial including the administration of a drug
  • Patients treated with azathioprine
  • Persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Sections L. 3212-1 and L. 3213-1 and persons admitted to a health or social institution for purposes other than research (see CSP Article L.1121-6)
  • Patients intolerant to hypouricemic treatments
  • Unable to use the internet
  • Difficulty understanding French
  • Illiteracy
  • Pregnant womenor breastfeeding mothers (see PHC article L.1121-5)
  • Major persons subject to a measure of legal protection or unseeding to express consent (see PHC Article L.1121-8)
  • Persons not affiliated to a social security plan or beneficiaries of such a plan (see PHC Article L.1121-8-1)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Gout is secondary to urate crystal deposition after chronic elevation of serum urate level (SUL). Long-term lowering SUL below 360 µmol/L allows dissolution of deposited crystals and disease cure. There is currently a paradoxical observation: while urate-lowering therapy (ULT) is available and efficient there is an increase of gout prevalence and severity. The apparent failure of ULT in gout management is due to several causes including unadjusted dosage, no SUL verification, irregular follow-up and low treatment compliance.

Read full original descriptionShow less

In contrast, a nurse-led treat-to-target (T2T) strategy with regular adaptations of ULT until reaching SUL target allows gout cure in more than 90% of patients. We hypothesize that an electronic messaging-led T2T strategy will allow obtaining similar results.

The aim of this study is to demonstrate that email-led T2T strategy during ULT is superior to usual care.

The 2 groups in the trial

  • E-mail follow-up groupTreatment being tested

    Email-led treat-to-target strategy with regular adaptation of ULT via electronic messaging

    Treatment: Cleanweb electronic messaging ePro

  • Usual follow-up groupExisting treatment, for comparison

    Adaptation and follow-up of ULT according to referring physician's habits

    Treatment: Usual follow-up

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
4 February 2026